Therapeutic potential of neuropeptide Y (NPY) receptor ligands
暂无分享,去创建一个
[1] R. Quirion,et al. Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5). , 2000, Canadian journal of physiology and pharmacology.
[2] J. Nurnberger,et al. Neuropeptide Y receptor genes are associated with alcohol dependence, alcohol withdrawal phenotypes, and cocaine dependence. , 2008, Alcoholism, clinical and experimental research.
[3] P. Widdowson,et al. Regulation of Neuropeptide Y Release by Neuropeptide Y Receptor Ligands and Calcium Channel Antagonists in Hypothalamic Slices , 1999, Journal of neurochemistry.
[4] W. Kraus,et al. Neuropeptide Y Gene Polymorphisms Confer Risk of Early-Onset Atherosclerosis , 2009, PLoS genetics.
[5] L.,et al. Isolation and characterization of a new pancreatic polypeptide hormone. , 1975, The Journal of biological chemistry.
[6] P. Mermelstein,et al. Calcitonin Gene-Related Peptide Regulates Expression of Neurokinin1 Receptors by Rat Spinal Neurons , 2003, The Journal of Neuroscience.
[7] Zhang Jy,et al. Effects of neuropeptide Y , 1993 .
[8] R. Quirion,et al. Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice , 2003, Behavioural Brain Research.
[9] Jason U Tilan,et al. Chronic Stress, Combined with a High‐Fat/High‐Sugar Diet, Shifts Sympathetic Signaling toward Neuropeptide Y and Leads to Obesity and the Metabolic Syndrome , 2008, Annals of the New York Academy of Sciences.
[10] T. Adrian,et al. Peptide YY abnormalities in gastrointestinal diseases. , 1986, Gastroenterology.
[11] G. Ordway,et al. Reduced Neuropeptide Y Concentrations in Suicide Brain , 1992, Journal of neurochemistry.
[12] D. Tracey,et al. Peripheral hyperalgesia in experimental neuropathy: exacerbation by neuropeptide Y , 1995, Brain Research.
[13] Motonao Nakamura,et al. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[14] G. Kaur,et al. On the intrinsic regulation of neuropeptide Y release in the mammalian suprachiasmatic nucleus circadian clock , 2010, The European journal of neuroscience.
[15] D. Erlinge,et al. Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP , 1994, Regulatory Peptides.
[16] M. Ando,et al. Modulation of neuropeptide Y receptors for the treatment of obesity , 2009, Expert opinion on therapeutic patents.
[17] H. Herzog,et al. Evidence from knockout mice for distinct implications of neuropeptide-Y Y2 and Y4 receptors in the circadian control of locomotion, exploration, water and food intake , 2009, Neuropeptides.
[18] R. Rimondini,et al. Blockade of central neuropeptide Y (NPY) Y2 receptors reduces ethanol self-administration in rats , 2002, Neuroscience Letters.
[19] M. Dickie,et al. Obese, a new mutation in the house mouse. , 1950, The Journal of heredity.
[20] C. Ehlers,et al. The effects of social isolation on neuropeptide Y levels, exploratory and anxiety-related behaviors in rats , 2006, Pharmacology Biochemistry and Behavior.
[21] H. Cox,et al. Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa , 2002, British journal of pharmacology.
[22] C. Wahlestedt,et al. Neuropeptide Y (NPY) and the central nervous system: Distribution effects and possible relationship to neurological and psychiatric disorders , 1989, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[23] R. Rimondini,et al. Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence , 2005, Neuroscience Letters.
[24] S. Bloom,et al. The therapeutic potential of gut hormone peptide YY3-36 in the treatment of obesity , 2005, Expert opinion on investigational drugs.
[25] R. Palmiter,et al. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y , 1996, Nature.
[26] M. Michel. Neuropeptide Y Receptors , 2008 .
[27] E. Potter,et al. Role of neuropeptide Y Y2 receptors in modulation of cardiac parasympathetic neurotransmission , 2002, Regulatory Peptides.
[28] Jason U Tilan,et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome , 2007, Nature Medicine.
[29] A. Steiger,et al. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men , 2000, Neuropharmacology.
[30] J. Eisman,et al. Greater Bone Formation of Y2 Knockout Mice Is Associated with Increased Osteoprogenitor Numbers and Altered Y1 Receptor Expression* , 2007, Journal of Biological Chemistry.
[31] T. Hökfelt,et al. Neuropeptide tyrosine and pain. , 2007, Trends in pharmacological sciences.
[32] Roseanne Norris,et al. The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.
[33] S. Whitebread,et al. A receptor subtype involved in neuropeptide-Y-induced food intake , 1996, Nature.
[34] J. Shine,et al. Cloned human neuropeptide Y receptor couples to two different second messenger systems. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[35] V. Mutt,et al. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides , 1980, Nature.
[36] P. Ernfors,et al. Assessment of ethanol consumption and water drinking by NPY Y2 receptor knockout mice , 2004, Peptides.
[37] F. Sallee,et al. Relevance of neuropeptide Y (NPY) in psychiatry. , 2007, Current topics in medicinal chemistry.
[38] H. Cox. Neuropeptide Y receptors; antisecretory control of intestinal epithelial function , 2007, Autonomic Neuroscience.
[39] S. Tufik,et al. Orexin activation precedes increased NPY expression, hyperphagia, and metabolic changes in response to sleep deprivation. , 2010, American journal of physiology. Endocrinology and metabolism.
[40] G. Glavin,et al. Effects of neuropeptide Y and [Leu31,Pro34] neuropeptide Y on experimental gastric lesion formation and gastric secretion in the rat. , 1993, The Journal of pharmacology and experimental therapeutics.
[41] L. Niskanen,et al. Leucine7 to proline7 polymorphism in prepro-NPY gene and femoral neck bone mineral density in postmenopausal women. , 2004, Bone.
[42] B. McDermott,et al. Evidence for Y1 and Y2 subtypes of neuropeptide Y receptors linked to opposing postjunctional effects observed in rat cardiac myocytes. , 1997, European journal of pharmacology.
[43] K. Kodukula,et al. Cloning and Functional Expression of a cDNA Encoding a Human Type 2 Neuropeptide Y Receptor (*) , 1995, The Journal of Biological Chemistry.
[44] J. Eisman,et al. Hypothalamic Regulation of Cortical Bone Mass: Opposing Activity of Y2 Receptor and Leptin Pathways , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[45] P. Ernfors,et al. Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor , 2001, Nature.
[46] C. Wahlestedt,et al. Selective and Brain Penetrant Neuropeptide Y Y2 Receptor Antagonists Discovered by Whole-Cell High-Throughput Screening , 2010, Molecular Pharmacology.
[47] J. Eisman,et al. Novel Role of Y1 Receptors in the Coordinated Regulation of Bone and Energy Homeostasis* , 2007, Journal of Biological Chemistry.
[48] P. Arner,et al. Common neuropeptide Y2 receptor gene variant is protective against obesity among Swedish men , 2006, International Journal of Obesity.
[49] Yihai Cao,et al. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[50] M. Cha,et al. Modulation of Neuropathic Pain by Galanin and Neuropeptide Y at the Level of the Medulla in Rats , 2009, The International journal of neuroscience.
[51] R. Palmiter,et al. Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[52] R. Barker,et al. Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis , 2011, Hippocampus.
[53] D. Smiley,et al. The Neuropeptide Y Y1 Antagonist, 1229U91, A Potent Agonist for the Human Pancreatic Polypeptide-Preferring (NPY Y4) Receptor , 1998, Peptides.
[54] D. Larhammar,et al. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. , 1992, The Journal of biological chemistry.
[55] T. Branchek,et al. Cloning and Functional Expression of a Human Y4 Subtype Receptor for Pancreatic Polypeptide, Neuropeptide Y, and Peptide YY (*) , 1995, The Journal of Biological Chemistry.
[56] T. Adrian,et al. NEUROPEPTIDE Y IN PHAEOCHROMOCYTOMAS AND GANGLIONEUROBLASTOMAS , 1983, The Lancet.
[57] Herbert Herzog,et al. Y4 receptor knockout rescues fertility in ob/ob mice. , 2002, Genes & development.
[58] D. Mcfadden,et al. NPY family of hormones: clinical relevance and potential use in gastrointestinal disease. , 2007, Current topics in medicinal chemistry.
[59] J. Kitlinska,et al. Neuropeptide Y (NPY) in neuroblastoma: Effect on growth and vascularization , 2007, Peptides.
[60] R. Joehl,et al. Pancreatic polypeptide inhibits amylase release by rat pancreatic acini. , 1986, The Journal of surgical research.
[61] E. Arenas,et al. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor , 1999, Nature Medicine.
[62] G. Sperk,et al. Neuropeptide Y in the dentate gyrus. , 2007, Progress in brain research.
[63] W. T. Chen,et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. , 1998, Circulation research.
[64] A. Zengin,et al. Neuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat , 2010, Trends in Endocrinology & Metabolism.
[65] V. Mutt,et al. Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide , 1982, Nature.
[66] N. Tamamaki,et al. Mechanisms of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Inhibition of Identified Green Fluorescent Protein-Expressing GABA Neurons in the Hypothalamic Neuroendocrine Arcuate Nucleus , 2005, The Journal of Neuroscience.
[67] Rachel L. Batterham,et al. Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.
[68] R. Rimondini,et al. Differential expression of NPY and its receptors in alcohol-preferring AA and alcohol-avoiding ANA rats. , 2001, Alcoholism, clinical and experimental research.
[69] A. Pitkänen,et al. Neuropeptide Y overexpression using recombinant adenoassociated viral vectors , 2009, Neurotherapeutics.
[70] X. T. Zhao,et al. Fat-induced ileal brake in the dog depends on peptide YY. , 1996, Gastroenterology.
[71] L. Grundemar. Multiple receptors and multiple actions , 1997 .
[72] C. Wahlestedt,et al. Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides , 1986, Regulatory Peptides.
[73] A. Sollevi,et al. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. , 1990, Cardiovascular research.
[74] A. Beck‐Sickinger,et al. First selective agonist of the neuropeptide Y1‐receptor with reduced size , 2009, Journal of peptide science : an official publication of the European Peptide Society.
[75] G. Greeley,et al. Characterization of Two Novel Proabsorptive Peptide YY Analogs, BIM-43073D and BIM-43004C , 2004, Digestive Diseases and Sciences.
[76] D. Allison,et al. PYY3‐36 as an anti‐obesity drug target , 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[77] D. Reis,et al. Identification of cultured cells selectively expressing Y1-, Y2-, or Y3-type receptors for neuropeptide Y/peptide YY. , 1992, Life sciences.
[78] M. Devor,et al. Chemically Mediated Cross-Excitation in Rat Dorsal Root Ganglia , 1996, The Journal of Neuroscience.
[79] J. Polak,et al. NEUROPEPTIDE TYROSINE (NPY)—A MAJOR CARDIAC NEUROPEPTIDE , 1983, The Lancet.
[80] Bengt Långström,et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. , 2006, Cell metabolism.
[81] P. Mantyh. Neurobiology of substance P and the NK1 receptor. , 2002, The Journal of clinical psychiatry.
[82] C. Strader,et al. Cloning and Expression of a Novel Neuropeptide Y Receptor* , 1996, The Journal of Biological Chemistry.
[83] G. Koob,et al. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. , 1993, Science.
[84] R. Murison,et al. Intracerebroventricular neuropeptide Y protects against stress-induced gastric erosion in the rat. , 1987, European journal of pharmacology.
[85] T. Hökfelt,et al. The neuropeptide tyrosine Y1R is expressed in interneurons and projection neurons in the dorsal horn and area X of the rat spinal cord , 2006, Neuroscience.
[86] M. Michel. Neuropeptide Y and Drug Development , 1998 .
[87] Ruihua Shi,et al. Correlation of Gut Hormones with Irritable Bowel Syndrome , 2008, Digestion.
[88] Yun Feng,et al. Molecular Characterization of a Second Mouse Pancreatic Polypeptide Receptor and Its Inactivated Human Homologue* , 1996, The Journal of Biological Chemistry.
[89] H. Herzog,et al. NPY regulation of bone remodelling , 2009, Neuropeptides.
[90] T. Hökfelt,et al. Distribution of neuropeptide Y Y1 receptors in rodent peripheral tissues , 2002, The Journal of comparative neurology.
[91] W. Colmers,et al. Opioid-like actions of neuropeptide Y in rat substantia gelatinosa: Y1 suppression of inhibition and Y2 suppression of excitation. , 2004, Journal of neurophysiology.
[92] T. Hökfelt,et al. Neuropeptide Y2 receptor protein is present in peptidergic and nonpeptidergic primary sensory neurons of the mouse , 2005, The Journal of comparative neurology.
[93] J. P. Hobson,et al. Neuropeptide Y induces migration , proliferation , and tube formation of endothelial cells bimodally via Y 1 , Y 2 , and Y 5 receptors , 2006 .
[94] G. Ronnett,et al. Neuropeptide Y functions as a neuroproliferative factor , 2001, Nature.
[95] P. Ernfors,et al. Attenuation of acute experimental colitis by preventing NPY Y1 receptor signaling. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[96] S. Southwick,et al. A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. , 2002, Archives of general psychiatry.
[97] M. Parmentier,et al. Agonist and antagonist activities on human NPFF2 receptors of the NPY ligands GR231118 and BIBP3226 , 2001, British journal of pharmacology.
[98] C. Wahlestedt,et al. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. , 1985, The Journal of pharmacology and experimental therapeutics.
[99] M. Heilig. The NPY system in stress, anxiety and depression , 2004, Neuropeptides.
[100] H. Akiho,et al. Inactivation of a Novel Neuropeptide Y/Peptide YY Receptor Gene in Primate Species* , 1996, The Journal of Biological Chemistry.
[101] D. Reis,et al. Neuropeptide Y Receptor Subtypes, Y1 and Y2 , 1990, Annals of the New York Academy of Sciences.
[102] P. Magni,et al. Relevance of the neuropeptide Y system in the biology of cancer progression. , 2007, Current topics in medicinal chemistry.
[103] Jason U Tilan,et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. , 2005, Cancer research.
[104] T. Branchek,et al. Expression Cloning and Pharmacological Characterization of a Human Hippocampal Neuropeptide Y/Peptide YY Y2 Receptor Subtype (*) , 1995, The Journal of Biological Chemistry.
[105] R. Palmiter,et al. Neuropeptide Y ( NPY ) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y 5 receptors , 2000 .
[106] R. Harris,et al. Patterns of gene expression are altered in the frontal and motor cortices of human alcoholics , 2002, Journal of neurochemistry.
[107] B. McDermott,et al. NPY and cardiac diseases. , 2007, Current topics in medicinal chemistry.
[108] X. S. Fu,et al. [Effects of neuropeptide Y]. , 1993, Sheng li ke xue jin zhan [Progress in physiology].
[109] C. Jayasena,et al. Gut Hormones: A Weight Off Your Mind , 2008, Journal of neuroendocrinology.
[110] N. Decarolis,et al. Hippocampal neurogenesis as a target for the treatment of mental illness: A critical evaluation , 2010, Neuropharmacology.
[111] R. Eglen,et al. Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist. , 1995, The Journal of pharmacology and experimental therapeutics.
[112] G. Schnorrenberg,et al. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. , 1999, European journal of pharmacology.
[113] G. Cornelissen,et al. Neuropeptide chronomics in clinically healthy young adults: circaoctohoran and circadian patterns , 2004, Peptides.
[114] G. Sperk,et al. Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus , 2010, Gene Therapy.
[115] Arndt F Schilling,et al. Leptin Inhibits Bone Formation through a Hypothalamic Relay A Central Control of Bone Mass , 2000, Cell.
[116] G. Thomas,et al. Hypothalamic Y2 receptors regulate bone formation. , 2002, The Journal of clinical investigation.
[117] S. Herness,et al. The neuropeptides CCK and NPY and the changing view of cell-to-cell communication in the taste bud , 2009, Physiology & Behavior.
[118] R. Palmiter,et al. Role of the Y5 neuropeptide Y receptor in feeding and obesity , 1998, Nature Medicine.
[119] J. Bue-Valleskey,et al. The role of neuropeptide Y in the antiobesity action of the obese gene product , 1995, Nature.
[120] P. Bonaventure,et al. In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor , 2010, Psychopharmacology.
[121] G. Aponte,et al. Meal‐induced peptide tyrosine tyrosine inhibition of pancreatic secretion in the rat , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.